

LL37 fragments have antimicrobial activity against *Staphylococcus epidermidis* biofilms and wound healing potential in HaCaT cell line

Saporito, Paola; Mouritzen, Michelle Vang; Løbner-Olesen, Anders; Jenssen, Håvard

Published in:
Journal of Peptide Science

DOI:
[10.1002/psc.3080](https://doi.org/10.1002/psc.3080)

Publication date:
2018

Document Version
Peer reviewed version

Citation for published version (APA):
Saporito, P., Mouritzen, M. V., Løbner-Olesen, A., & Jenssen, H. (2018). LL37 fragments have antimicrobial activity against *Staphylococcus epidermidis* biofilms and wound healing potential in HaCaT cell line. *Journal of Peptide Science*, 24(7), [3080]. <https://doi.org/10.1002/psc.3080>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact rucforsk@ruc.dk providing details, and we will remove access to the work immediately and investigate your claim.







**LL-37 fragments have antimicrobial activity against
Staphylococcus epidermidis biofilms and wound healing
potential in HaCaT cell line**

Journal:	<i>Journal of Peptide Science</i>
Manuscript ID	PSC-17-0147.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	16-Feb-2018
Complete List of Authors:	Saporito, Paola; Roskilde Universitet, Science and Environment; Kobenhavns Universitet Biologisk Institut, Biology Vang, Michelle; Roskilde Universitet, Department of Science and Environment Løbner Olesen, Anders; Kobenhavns Universitet Biologisk Institut, Biology Jenssen, Håvard ; Roskilde University,
Keywords:	Human cathelicidin LL-37, S. epidermidis, Biofilm eradication, Wound healing

SCHOLARONE™
Manuscripts

Peptides FK-12, KR-12 and VQ-12^{V26} derived from human LL-37 have antibiofilm properties. In addition, KR-12 and VQ-12^{V26} have wound healing potential and should be used as lead peptides for eradication of biofilms in catheters and infected wounds. Remarkably, in VQ-12^{V26} the single substitution aspartate to valine in position 26 leads to gain of antimicrobial function against *S. epidermidis* biofilms and enhanced wound closure *in vitro*.



LL-37 fragments have antimicrobial activity against *Staphylococcus epidermidis* biofilms and wound healing potential in HaCaT cell line.

Saporito Paola, Vang Michelle, Løbner-Olesen Anders, Jensen Håvard

Saporito Paola^{a,b}, Vang Michelle^b, Løbner-Olesen Anders^a, Jenssen Håvard^{b*}.

LL-37 fragments have antimicrobial activity against *Staphylococcus epidermidis* biofilms and wound healing potential in HaCaT cell line

* Correspondence to Håvard Jenssen Department of Science and Environment, Roskilde University, Universitetsvej 1, Postboks 260, 4000 Roskilde, Denmark

^a Section for Functional Genomics and Center for Bacterial Stress Response and Persistence, Department of Biology, University of Copenhagen, Copenhagen, Denmark

^b Department of Science and Environment, Roskilde University, Roskilde, Denmark

ABSTRACT

Staphylococcus epidermidis is a common nosocomial pathogen able to form biofilms in indwelling devices, resulting in chronic infections which are refractory to antibiotics treatment. Staphylococcal biofilms are also associated with the delayed reepithelization and healing of chronic wounds. The human cathelicidin peptide LL-37 has been proven active against *S. epidermidis* biofilms *in vitro* and to promote wound healing. As previous studies have demonstrated that fragments of LL-37 could possess an equal antibacterial activity as the parent peptide, we tested whether shorter (12-mer) synthetic fragments of LL-37 maintained the anti-biofilm and/or immune modulating activity, aiming at the identification of essential regions within the LL-37 parent sequence. Three fragments of LL-37 displayed improved activity against *S. epidermidis* in terms of biofilm inhibition and eradication, a reduced cytotoxicity to human keratinocytes and erythrocytes. In addition, KR-12 and VQ-12^{V26} enhanced wound healing potential, relative to LL37. FK-12 and KR-12 are truncated version of the cathelicidin, previously reported as valid antimicrobials, whereas VQ-12^{V26} is a single substituted LL-37 fragment. Remarkably, the single substitution aspartic acid to valine in position 26 caused gain of antimicrobial function in the inactive VQ-12 fragment. The combination of anti-biofilm, wound healing potential and low cytotoxicity makes KR-12 and VQ-12^{V26} promising therapeutic agents and lead compounds for further improvement and understanding of anti-biofilm and wound healing properties.

1
2
3 *Keywords: Human cathelicidin LL-37; S. epidermidis; Biofilm eradication; Wound healing*
4
5
6
7

8 INTRODUCTION 9

10
11 The excessive use of antibiotics in human and veterinary medicine, as well as agriculture, harms the
12 community in the long term [1-5]. In fact, the misuse of antibiotics accelerates the natural-
13 occurring mutation-driven antimicrobial resistance by selecting notsusceptible bacteria which can
14 then spread vertically or horizontally [6]. Multidrug resistant bacteria or superbugs are now
15 commonly found and impact both in and outside of hospitals and retirement homes. The scientific
16 community is therefore pressured to find new and more effective drugs to halt this treat.
17
18
19
20
21
22
23

24 A promising alternative to antibiotics resides in the broad-spectrum and evolutionarily-conserved
25 antimicrobial peptides (AMPs), or host defense peptides which may work as effectors of the
26 immune response triggered in eukaryotes, upon infection by microbial agents [7, 8]. AMPs are
27 generally short (10- 50 amino acids) and characterized by an amphiphilic configuration, derived
28 from the presence of cationic residues on one side of the peptide and hydrophobic residues on the
29 opposite side [9]. The amphipathic nature of AMPs allows them to interact with negatively-charged
30 bacterial membranes and perturb the membrane bilayer, promoting either cell lysis, upon membrane
31 disruption, or inhibition of intracellular processes such as nucleic acids and proteins synthesis
32 [10,11].
33
34
35
36
37
38
39
40
41
42
43

44 Humans express a variety of AMPs, grouped into three major classes, namely cathelicidin,
45 defensins and histatins which differ in structure and residue composition [12]. There is one unique
46 human cathelicidin gene, transcribed as the pro-peptide hCAP18 and released as the active
47 cathelicidin peptide LL-37, upon digestion by serine proteases [13]. LL-37 has pleiotropic activities
48 both on pathogens and host cells: it is able to form pores through bacterial membranes, thus
49 exerting an antimicrobial effect, while it also is modulating defense mechanisms [14]. Furthermore,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 LL-37 has been demonstrated to have a positive effect on wound healing, both *in vitro* and *in vivo*,
4
5 by increasing angiogenesis [15], re-epithelization [16], and chemotaxis [17]. The skin constitutes
6
7 the first line of defense to the human body, and is itself shielded by pathogen bacterial colonization,
8
9 thanks to the constitutive expression of low-levels of LL-37 by keratinocytes. Once the epithelial
10
11 barrier fails due to infection or injury, the rate of LL-37 expression is further increased through the
12
13 active synthesis by keratinocytes themselves and by the recruited immune cells such as neutrophil
14
15 and mast cells. The increased levels of LL-37 halt bacterial proliferation while promoting re-
16
17 epithelialization of the skin [18].
18

19
20 At the same time, the skin constitutes an optimal niche for a diversified microbiota, comprising the
21
22 opportunistic pathogen *S. epidermidis*, which normally grows as a commensal but can turn
23
24 pathogenic in immunocompromised patients when the epidermal barrier is breached [19,20]. A
25
26 beneficial effect of *S. epidermidis* is its ability to prevent an excessive inflammatory response
27
28 during re-epithelialization of damaged skin. This results from the *S. epidermidis* lipotechoic acid
29
30 interaction with Toll-like receptor 2 on keratinocytes, which in turn prevents the release of the pro-
31
32 inflammatory cytokine TNF- α [19]. *S. epidermidis* can penetrate the ulcerated epidermis to reach
33
34 the bloodstream and it is the most common cause of primary bacteremia and infection of indwelling
35
36 medical devices, particularly in immunocompromised individuals and neonates [21]. *S. epidermidis*
37
38 infections are increasingly resistant to antibiotics such as penicillins, aminoglycosides and
39
40 quinolones [22]. *S. epidermidis* causes the onset of chronic infections, due to its ability to escape
41
42 host defense mechanisms [22,23].
43
44
45

46
47 Both these characteristics of *S. epidermidis* infections relate to the pathogenic species ability to
48
49 attach to solid surfaces and form a social community called biofilm, where bacteria are embedded
50
51 into a self-secreted matrix composed mainly by exopolymers and DNA. The biofilm confers a
52
53 protective niche to the bacteria and provides the bacterial population a reservoir of pathogens, thus
54
55 enabling the persistence of the infection [23].
56
57
58
59
60

1
2
3 In particular, the naturally occurring antimicrobial peptide LL-37 has been proven effective in
4 inhibiting biofilm formation [24, 25]. LL-37 is active against *S. epidermidis*: it is constitutively
5 expressed in the skin of the newborn, where it helps maintaining the microbiota by inhibiting *S.*
6
7 *epidermidis* growth [23].
8
9

10
11 A common approach in drug design is to make derivatives of natural products. Because, natural and
12 synthetic AMPs constitute a promising alternative to antibiotics, we assessed the antimicrobial
13 effect of truncated versions of LL-37 peptide against *S. epidermidis* and evaluated their efficacy as
14 biofilm inhibitors or eradicators in comparison to the parent peptide. The aim was to identify the
15 minimal sequence needed for activity, while aiming at reducing the cost and improving the ease of
16 production of a lead compound useful for further design and activity improvement.
17
18

19 Therefore, we decided to scan the LL-37 sequence, by testing different fragments with a fixed
20 length of 12 mer. The definite length of 12-mer was previously used as bioinformatic descriptor to
21 identify active antimicrobials peptides derived from bactenecin [26]. Moreover, previous studies
22 have tested the activity of 12 mer long fragments of LL-37, namely fragment KR-12, identified as a
23 α -helix peptide, bearing the minimal antimicrobial sequence against *E. coli* [11] (Wang G., 2008)
24 and fragment LL-12, proven to be antimicrobial inactive [27]. Those fragments were among the
25 ones tested in our study.
26
27

28 In addition, the fragments ability to induce migration, a crucial aspect for wound healing, was
29 tested. Cytotoxicity of the fragments and their parent peptide LL-37 was assessed in human
30 keratinocytes and erythrocytes, respectively via lactate dehydrogenase release and hemolysis assay.
31 Here we demonstrate that three LL-37 fragments: FK-12, KR-12 and VQ-12^{V26} have an improved
32 activity against *S. epidermidis* in terms of biofilm inhibition and eradication, have a reduced
33 cytotoxicity to human keratinocytes and erythrocytes. In addition, KR-12 and VQ-12^{V26} enhance
34 keratinocytes migration more than the parent peptide.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

LL-37 derived peptides inhibit growth of planktonic *S. epidermidis*.

To test the antimicrobial potential of LL-37 derived peptides against planktonic *S. epidermidis*, the minimal inhibitory concentration (MIC) for selected peptides was determined (Table 1). The parent peptide LL-37 was more potent than most of the fragments, with just FK-12, KR-12 and VQ-12^{V26} being equal to the parent peptide.

Furthermore, the minimal biocidal concentrations (MBC) were determined for LL-37, FK-12, KR-12 and VQ-12^{V26}. The lowest concentrations revealing no bacteria growth on the solid medium were reported as the MBC values (Table 2). The observed MBC values matched with the 48 hours MIC values (data not shown). If the MIC/MBC was reported below 4, the action of all the compounds at the MIC value was inferred to as being bactericidal.

Sequence-activity relationship analysis

The simple alignment of the best acting fragments sequences did not allow the identification of a minimal sequence needed for antimicrobial activity, as no residue was strictly needed for the antimicrobial activity (Table 3). Splitting LL-37 in four similar size fragments composed of residues 1-12 (LL-12), 9-20 (SK-12), 21-32 (VQ-12) and 26-37 (DF-12) creates four inactive peptides.

The only antimicrobial peptides FK-12 and KR-12 share overlapping residues 18-28, however the deletion or addition of any of these residues had no real contribution to the overall activity, as the comparison to the partly overlapping peptides SK-12 and VQ-12 showed (Table 3).

Remarkably, the substitution of aspartic acid to valine in position 26 resulted in a drop in the MIC values for VQ-12^{V26} and VQ-12 (Table 1). The substitution aspartic acid to valine increased both the charge and hydrophobicity of the resulting peptide and affected the peptide bioactivity. This

1
2
3 suggests that the overall physicochemical properties, rather than the sequence itself, are the main
4
5 determinants for anti-biofilm activity.
6
7
8
9

12 13 **LL-37 derived peptides inhibit *S. epidermidis* biofilm formation *in vitro***

14
15
16 The antimicrobial properties of the LL-37 fragments were further investigated by focusing on their
17
18 inhibitory potential on *S. epidermidis* biofilm formation *in vitro*. This study was conducted by
19
20 biofilm formation assay in polypropylene microtiter plates and was aimed at defining the essential
21
22 residues for the previously reported antibiofilm properties of LL-37 [23, 24]. In a preliminary
23
24 screening, all fragments were tested at a wider concentrations range (100-6.25 µg/ml) to select the
25
26 best acting peptides and their optimal concentrations (Figure 1). The growth medium Mueller
27
28 Hinton Broth (MHB) was used both as sterility control and to detect unspecific binding of the
29
30 crystal violet dye to inorganic matter. The fragments FK-12, KR-12 and VQ-12^{V26} were the best
31
32 biofilm inhibitors within the group, with the more pronounced anti-biofilm effects at the highest
33
34 concentrations tested, which corresponded to their 2 x MIC values
35
36
37
38
39
40

41 **The fragments FK-12, KR-12 and VQ-12^{V26} inhibit *S. epidermidis* biofilm formation**

42
43
44 To compare the anti-biofilm activities of LL-37 and its fragments FK-12, KR-12 and VQ-12^{V26}, all
45
46 these peptides were used at concentrations ranging from 100 to 12.5 µg/ml and tested for their *S.*
47
48 *epidermidis* biofilm inhibition properties. The anti-biofilm activities of fragments FK-12, KR-12
49
50 and VQ-12^{V26} were higher than that of LL-37, reducing biofilm biomass by more than 80%. In fact,
51
52 the peptides FK-12, KR-12 and VQ-12^{V26} inhibited biofilm formation at the 100, 50 and 25 µg/ml
53
54 concentrations (Figure 2). FK-12 slightly inhibited biofilm formation also at 12.5 µg/ml
55
56 concentration whereas KR-12 and, to a less extent also VQ-12^{V26}, promoted biofilm formation at
57
58
59
60

1
2
3 the same concentration. At the tested concentrations, LL-37 had a minimal impact on *S.*
4 *epidermidis* biofilm: besides having a slight inhibitory effect at sub-MIC concentrations (25 and
5 12.5 µg/ml), it had clearly no effect at higher concentrations and apparently it had even a pro-
6
7 biofilm effect at 50 µg/ml.
8
9

10 11 12 13 14 15 **LL-37 derived peptides eradicate *S. epidermidis* biofilms *in vitro***

16
17 To investigate whether the antimicrobial effect observed for FK-12, KR-12 and VQ-12^{V26} was
18 directed against bacteria in the biofilm rather than in the planktonic state, a biofilm eradication
19 assay was performed on 1-day-old *S. epidermidis* biofilm. In a similar assay, all the not-adhering
20 planktonic cells are removed from the wells by aspiration and repeated washing steps. Therefore,
21 any observed effect is directed against biofilm embedded cells or biofilm structural components.
22
23
24
25
26
27
28

29 While the parent peptide LL-37 proved inactive against preformed *S. epidermidis* biofilms, a clear
30 anti-biofilm effect was observed for the FK-12, KR-12 and VQ-12^{V26} fragments at their 2 × MIC
31 concentration. In particular, the fragment FK-12 was the strongest eradicator, capable of removing
32 80% of the formed biofilm (Figure 3).
33
34
35
36
37

38 **LL-37 derived peptides have low cytotoxicity**

39
40 To evaluate the effect of FK-12, KR-12, VQ-12^{V26} and LL-37 on the host cells, primary cultures of
41 human erythrocytes and the human keratinocytes cell line HaCaT were challenged with the
42 peptides. To allow for correlation to the antimicrobial assays, equivalent concentrations and
43 administration times were used. *In vitro* cytotoxicity was assessed by lactate dehydrogenase (LDH)
44 release assay in the HaCaT cell line and by hemolysis assay in erythrocytes. The fragments FK-12,
45 KR-12 and VQ-12^{V26} were clearly less toxic to human erythrocytes and keratinocytes than their
46 parent peptide LL-37. In fact, at 100 µg/ml, the percent of cytotoxicity to HaCaT cells was above
47 30% for LL-37 and below 10% for FK-12, KR-12, VQ-12^{V26}, with the peptide KR-12 being the less
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 toxic of the three fragments. At 50 µg/ml, the cytotoxicity of LL-37 was slightly above 10%,
4
5 whereas all the three fragments were not cytotoxic (Figure 4). Likewise, the parent peptide LL-37
6
7 was more cytotoxic to human erythrocytes than its fragments: at all the concentrations tested the
8
9 percent of hemolysis was close to 0 for FK-12, KR-12, VQ-12^{V26}, whereas for LL-37 the percent of
10
11 hemolysis was above 20% at 100 µg/ml and decreased for decreasing concentrations. Remarkably,
12
13 at the lowest concentration of 6.25 µg/ml, the hemolysis induced by LL-37 was still higher than the
14
15 one observed upon administration of the fragments FK-12, KR-12, VQ-12^{V26} at the concentration of
16
17 100 µg/ml. (Figure 5). Both these cytotoxicity data, taken together with the antimicrobial activity,
18
19 demonstrated that the fragments have a better selectivity toward pathogens than the parent peptide
20
21 (Table 4). In addition, the results suggested that neither topical nor systemic administrations of the
22
23 fragments would be harmful to the recipient.
24
25
26
27
28
29

30 **LL-37 derived peptides have wound healing potential.**

31
32 Since LL-37 was previously reported to promote wound healing both *in vitro* and *in vivo*, the
33
34 wound healing properties of the set of peptides used in this study were assessed in an *in vitro*
35
36 scratch assay in HaCaT cells. All fragments were tested at 25 µg/ml concentrations, which
37
38 correspond to a quarter of their MIC values, and epidermal growth factor was used as positive
39
40 control, as previously described [28]. Shortly, the epidermal growth factor binds to the epidermal
41
42 growth factor receptor, which stimulates the mitogen-activated protein kinase (MAPK) pathway
43
44 resulting in increased migration of keratinocytes [29, 30]. LL-37 promotes keratinocytes migration
45
46 by epidermal growth factor receptor transactivation and STAT3 phosphorylation [31]. Remarkably,
47
48 all the fragments had a stronger effect than the parent LL-37 peptide (Figure 6). The LL-37
49
50 fragments were not cytotoxic to epithelial cells, but in addition showed wound healing potential,
51
52 with the highest percent of wound closure observed for fragments KR-12, VQ-12, VQ-12^{V26} and
53
54 IK-12, allowing us to infer that the wound healing activity should rely on the C-terminal half of the
55
56
57
58
59
60

parent peptide. Furthermore, and in contrast to what observed for their antimicrobial potential, VQ-12 and VQ-12^{V26} had a similar effect, thus suggesting that the residue in position 26 has not major impact on this activity.

The combination of antimicrobial and wound healing properties, together with low cytotoxicity, makes peptides KR-12, VQ-12^{V26} valuable as putative drugs for management of *S.epidermidis* infections in human skin.

CD spectra analysis

Circular dichroism (CD) analysis was performed to monitor the conformational changes of the set of peptides in water, water-2'2'2'trifluoroethanol (TFE) (1:4) and 20 mM SDS. The peptide LL-37 itself is reported to be unstructured in pure water and to adopt α -helical secondary structure when bound to lipid bilayer surfaces [11]. All the peptides were likewise unstructured in water and adopted an α -helical conformation in water-TFE with the sole exception of peptides SK-12, IK-12 and DF-12 (Figure 7). The inability to assume a helical conformation in TFE, an isotropic solvent that mimics membrane environment, could be the reason of lack of antimicrobial activity for these peptides. However, since both the fragments VQ-12^{V26} and VQ-12 were able to adopt the same conformation but were not equally potent antimicrobials, the helicity alone does not account for the observed activity. Remarkably, in 20 mM SDS all the peptides adopted an α -helical conformation, except for the random-coil peptide DF-12 and the β -strand peptide VQ-12^{V26}. As the inactive peptide VQ-12 and its active variant VQ-12^{V26} adopted different secondary structures, the ability to form β -conformation could be the discriminant for the biological activity observed.

In silico analysis: physicochemical properties as predictive tools for bioactivity

1
2
3 Physicochemical properties have been computed for the parent peptide LL-37 and its fragments, by
4 using chemo-informatics tool available on-line (ExpASy ProtParam) [32] In addition, a query on
5 the antimicrobial peptide database (APD) [33] had further added some insights into the fragments
6 properties, identified the already deposited LL-37 fragment KR-12 and enabled the prediction of its
7 antimicrobial activities (Table 5).
8
9
10
11
12

13
14 The physicochemical properties of the peptides and their bioactivity indicators were used to predict,
15 confirm and interpret the experimental results. As a general rule, AMPs are expected to have
16 molecular weight (Mw) < 10 kDa, isoelectric point (pI) ≥ 10 , net charge ≥ 2 , Hydrophobicity index
17 (HI) > 0.5 (using Eisenberg scale) and instability index (II) < 40. Furthermore, transmembrane
18 peptides have mean hydrophobicity (mH) < 0.2, hydrophobic peptides have positive GRAVY
19 values and negative- or close to 0- Boman indices (BI) [34].
20
21
22
23
24
25
26

27
28 Due to their short length, all the tested peptides fell in the optimal range value for their Mw.
29 Remarkably, all of them but DF-12 had optimal values of stability index, net charge and isoelectric
30 point. Therefore, its lack of activity was consistent with the predictions. FK-12, KR-12 and LL-37
31 had a hydrophobic index $mH > 0.5$, thus fitting in the AMP predictor values. In contrast, both the
32 active peptide for VQ-12^{V26} and its inactive counterpart VQ-12, had $mH < 0.5$. Therefore, this single
33 parameter did not allow to discriminate between active and inactive fragments. An alternative
34 hydrophobicity parameter, the hydrophobic moment μ_H , measures the separation of polar and
35 nonpolar amino acids along the peptide axis and it predicts the potential of helix formation for a
36 given peptide. The ADP database gave a helix pattern for any input peptide sequence. As per the
37 APD outputs, the FR-12 fragment might form an α -helix and it had at least 5 hydrophobic residues
38 on the same surface. It might interact with membranes and was predicted to be antimicrobial. The
39 same prediction of membrane interaction potential and antimicrobial activity was given for both the
40 biofilm active VQ-12^{V26} and biofilm inactive peptide VQ-12, both carrying 4 hydrophobic residues.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56 In contrast, the biofilm inactive peptides DF-12 and IK-12 were predicted to be not antimicrobial as
57
58
59
60

1
2
3 they do not have hydrophobic residues on the same surface and cannot form an α -helix long enough
4
5 to be considered antimicrobial. Therefore, when we compared the ADP database outputs with our
6
7 experimental results, the ADP prediction tool gave both false negative and false positive results. A
8
9 probable explanation is that the μ H is a poor predictor of helicity in the bound state, since the helix
10
11 formation would depend by helix-stabilizing side chain interactions. It has been proved that
12
13 peptides with the same hydrophobic moment have a differential binding affinity to the membranes
14
15 and that the sequence, rather than amino acids composition, has a major impact on the actual helix
16
17 formation [28]. Moreover, all the listed peptides had negative GRAVY values and positive Boman
18
19 indices.
20
21
22
23
24

25 Discussion

26
27
28 Human cathelicidin LL-37 is secreted in the skin where it acts as a natural AMP, able to halt the
29
30 proliferation of a plethora of pathogens by forming pores across bacterial membranes. *S.*
31
32 *epidermidis* is human skin commensal which can turn pathogenic in immunocompromised patients
33
34 and is able to form biofilm. Preliminary data have shown that LL-37 inhibits *S. epidermidis* biofilm
35
36 *in vitro* [23]. Our study aimed at identifying the minimal sequences needed for the antimicrobial
37
38 and anti-biofilm properties of the LL-37 peptide by testing the biological activities of LL-37
39
40 scrambled fragments and comparing them to those of the parent peptide. Antimicrobial properties
41
42 were evaluated against bacteria in their planktonic state, via the MIC assay, and against biofilm via
43
44 inhibition and eradication assays. The peptides FK-12, KR-12 and VQ-12^{V26} were the best
45
46 antimicrobial agents within the group of fragments analyzed. Remarkably, all of them had MIC
47
48 values equivalent or proximal to the parent peptide but appeared to be more efficient inhibitors and
49
50 eradicators of *S. epidermidis* biofilms.
51
52
53

54
55 Besides, as FK-12 and KR-12 acted as inhibitory to biofilms even at concentrations below their
56
57 MIC value, an additional explanation needs to be found. The death itself of some cells within the
58
59
60

1
2
3 bacterial population and their consequent lysis, mediated by autolysin E, would release extracellular
4 DNA and promote biofilm assembling in the remaining subpopulation [35]. The hypothesis arises
5 that the fragments and LL-37 would inhibit the biofilm formation by halting the programmed cell
6 death of bacterial sub-populations which in turn acted as a trigger for biofilm assembly.
7
8
9

10
11 The LL-37 fragment KR-12 is registered in the antimicrobial peptide database (APD), with ID
12 AP00608. It is described as an α -helix peptide with antimicrobial activity against *E. coli* K12 but
13 not cytotoxic to human cells [11]. The cytotoxicity data are consistent with our data. NMR analysis
14 of KR-12 in lipid micelles proved that this peptide forms an amphipathic helix with cationic side
15 chains which, upon binding, promote the clustering of bacterial membranes phosphatidylglycerols,
16 activating voltage dependent potassium channels and promoting signal transduction [11]. A similar
17 mechanism would most likely be valid also for the closely related fragment FK-12, but a definite
18 confirmation would require similar NMR analysis to be performed. In addition, the peptide FK-13,
19 which contains an additional arginine to FK-12, is reported as toxic to human cells [11]. This is
20 interesting, since the fragment FK-12 we studied is not toxic to human erythrocytes and
21 keratinocytes. Therefore, the removal of a single arginine in position 29 would result in the loss of
22 the peptide cytotoxicity against human cells.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 CD spectra analysis conducted in presence of the isotropic solvent TFE did not prove a direct
39 correlation between peptides secondary structure and antimicrobial activity. In fact, while the
40 peptides SK-12, IK-12 and DF-12 assumed a random coiled structure and were equally inactive as
41 an antimicrobial, all the other peptides folded into α -helices but were differentially active against *S.*
42 *epidermidis*. Therefore, the α -helical arrangement is not sufficient to predict and discriminate for
43 antimicrobial potential of the tested peptides. In contrast, in presence of SDS, an environment
44 which more closely mimics bacterial membranes, the active peptide VQ-12^{V26} adopted a β -strand
45 conformation, whereas the inactive peptide VQ-12 was α -helical. Therefore, the different biological
46 activity observed upon the substitution aspartate to valine could be associated to the different
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 secondary structure adopted by the peptides VQ-12 and VQ-12^{V26}. Aside from helicity, the
4
5 comparison among the fragments and the parent peptide clearly demonstrates that the shorter the
6
7 sequence the higher the antibiofilm effect, which most likely associates to the peptides ability to
8
9 penetrate the cellular membrane or biofilm matrix.

10
11
12 In addition, besides the crystal violet staining enables a good estimate of biofilm mass, it is not
13
14 informative on bacteria viability. Therefore, it is not possible to incontrovertibly define the peptides
15
16 effect as being bactericidal or, rather, directed against biofilm matrix components.

17
18
19 Remarkably, the fragments FK-12, KR-12 and VQ-12^{V26} have a better selectivity ratio; lower
20
21 toxicity to the host and improved potency against the pathogen, than the parent peptide (Table 4). It
22
23 has been proposed that the pleiotropic functions of LL-37 are mapped on different regions of the
24
25 peptide. The hydrophobic N-terminal¹⁻¹³ has been associated with oligomerization, hemolytic and
26
27 chemotactic properties, the main antimicrobial properties reside within the middle-region¹⁷⁻³¹, while
28
29 the C-terminal³²⁻³⁷ is involved in the LL-37 tetramer formation at physiological pH [11, 12]. The
30
31 LL-37 tetramer is maintained in zwitterionic membranes, as is the case of human erythrocytes
32
33 membranes. Instead the LL-37 tetramer dissociates in anionic bacterial membranes where it binds
34
35 lipopolysaccharide in Gram-negative or phosphatidylglycerols in Gram-positive bacteria, and forms
36
37 a long amphipathic α -helix that inserts into and disrupts the bacterial membranes [11]. The lack of
38
39 the LL-37 N-terminal region in the fragments may explain the reduced hemolytic activity observed,
40
41 while elevated binding propensity to acidic bacteria phospholipids, as the antimicrobial domain is
42
43 maintained within the fragments FK-12 and KR-12.

44
45
46
47
48 By substituting the aspartic acid residue in position 26 with a valine, it was possible to switch the
49
50 inactive peptide VQ-12 into the potent biofilm inhibitor and eradicator VQ-12^{V26}. This substitution
51
52 correlates with an increase in net charge (2+ to 3+), isoelectric point, aliphatic index and
53
54 hydrophobic dipolar moment, whereas all the other physicochemical parameters are concomitantly
55
56 decreased (Table 5). In addition, this substitution results in a different conformation which
57
58
59
60

1
2
3 correlates with the biological activity observed. Regarding the wound healing potential, fragments
4 KR-12 and VQ-12^{V26} had an increased effect on migration, whereas LL-12 reduced the
5 keratinocytes migration compared to the untreated control. As the highest percent of wound closure
6 was obtained upon stimulation with fragments KR-12, VQ-12, VQ-12^{V26} and IK-12, the healing
7 property most likely rely on the C-terminal half of the parent peptide. In contrast to what observed
8 for their antimicrobial potential, VQ-12 and VQ-12^{V26} had a similar effect on wound closure, thus
9 suggesting that the residue in position 26 has not major impact on this activity. We suggest to
10 further assess this hypothesis and implement the antibiofilm properties by a rational drug design,
11 using these peptides as lead compounds and test their eradication properties on yet more established
12 biofilms and mixed species biofilms. The precise mechanism of interaction with the pathogen and
13 the antimicrobial mode of action should be further investigated.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Conclusion**

31
32 In this study, we assessed the antimicrobial effect of truncated versions of LL-37 peptide against *S.*
33 *epidermidis* by testing their potential as biofilm inhibitors or eradicators in comparison to the parent
34 peptide. The fragments FK-12, KR-12 and VQ-12^{V26} exhibited an increased antimicrobial effect
35 compared to the parent peptide by inhibiting bacterial attachment, biofilm growth and disrupting
36 established biofilms. In addition, fragments KR-12 and VQ-12^{V26} increased migration of HaCaT
37 cells in an *in vitro* wound model. At the same time, they demonstrated a reduced cytotoxicity
38 toward human erythrocytes and HaCaT cells. We propose to further investigate the effect of amino
39 acids substitution in the peptides set used in this study. This warrant and extended SAR study to
40 investigate correlation of peptide sequence and biological activity both against *S. epidermidis*
41 biofilm and toward wound healing.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Peptides used in the study

All human LL-37 variants peptides used in the study are 12 residues long and correspond to different, in some cases overlapping, fragments of the human cathelicidin peptide LL-37 and were purchased from GenScript. Two fragments have completely overlapping sequences, except for one single residue in position 26, which is either a valine or an aspartic acid (Table 1).

HaCaT cell line

The HaCaT cell line was kindly donated from David Gram Naym. The cells were grown in Dulbecco's modified eagle medium (DMEM) with glutamax (Thermofisher, 31966-021), 10% FBS (Gibco, 10270), 100 units/ml penicillin, and streptomycin (Sigma, P0781). The cells were subcultivated approximately every third day, by washing with PBS and trypsinizing (Sigma, Lot T3924).

Wound healing

Wound healing was assessed by a scratch assay performed in 48 wells where 7.5×10^4 /well cells were seeded and incubated 24 hours to reach 95% confluency. The following day, the wells were washed with PBS, scratched manually with a 200 μ l pipet tip and stimulated with 25 μ g/ml of peptides diluted in DMEM containing 2% FBS. Epidermal growth factor was used as positive control. The migration of the HaCaT cells were monitored with the optical camera system called oCelloScope (BioSense, Denmark) for 24 hours [36]. The oCelloScope used the software

1
2
3 UniExplorer (8.0.0.7144 (RL3)). Closure of the scratch was calculated as a percentage for time 0 and
4
5 24 and compared to the untreated control.
6
7
8
9

10 **Bacterial strain**

11
12
13 *Staphylococcus epidermidis* (HJ 056) from our laboratory strains collection was obtained from
14
15 Statens Serum Institut in Copenhagen, Denmark and verified as an *S. epidermidis* by sequencing of
16
17 the *dnaN* gene. Frozen bacteria were streaked on Luria Bertani (LB) agar plates in sterile conditions
18
19 and allowed to grow at 37°C for 18 hours, until uniform colonies were observed. Agar plates were
20
21 stored in the refrigerator and used for a maximum of 14 days as reservoir of bacteria for the
22
23 experiment replicates. For every assay, single colonies were transferred to MHB and maintained
24
25 overnight at 37°C in constant agitation to allow bacterial replication.
26
27
28
29
30

31 **MIC assay**

32
33
34 The minimal inhibitory concentrations (MIC) for the tested compounds were determined according
35
36 to the microtiter broth dilution method [37]. Briefly, bacteria cultures grown overnight in constant
37
38 agitation at 37° C were diluted (1:50) in fresh growth medium and allowed to grow in the same
39
40 conditions of temperature and shaking. Once the OD₆₀₀ equals to 0.4, the bacterial culture was
41
42 further diluted in fresh MHB (1:500) to obtain a final bacterial inoculum ranging between 2-8 ×10⁵
43
44 cfu/ml. Eventually, 90 µl of this bacterial suspension were inoculated per well in the microtiter
45
46 plate, previously filled with 10 µl of serial dilutions of the test peptides, starting from an initial
47
48 concentration equal to 10 times the intended one (to take into account the final 1:10 dilution in the
49
50 bacterial suspension). Multiple wells were used as growth medium sterility control. An additional
51
52 check of the sterility conditions, as well as of the real bacterial concentration seeded, was obtained
53
54 by plating on agar a further 1:500 dilution of the inoculum. Both the microtiter and the agar plates
55
56
57
58
59
60

1
2
3 were placed in the incubator at 37 C for 18 hours. The MIC was determined as the peptide
4 concentration giving no visible bacterial growth. The sterility of the working conditions was
5 assessed by the uniformity of morphology of bacterial colonies and the inoculum concentration was
6 confirmed by counting of the bacterial colonies. After MIC reading, plates were further incubated
7 for 1 day and plate was read again after 48 hours.
8
9
10
11
12
13
14
15
16

17 **MBC assay**

18
19 Minimal biocidal concentrations (MBC) were determined by plating on solid MHB agar 100 µl of
20 bacterial suspensions from the MIC plate assay wells corresponding to and above the MIC values.
21 Plates where no growth was visible after 24 hours of incubation at 37°C were considered to
22 correspond to the biocidal concentration.
23
24
25
26
27
28
29
30
31

32 **Biofilm assay**

33
34 Biofilm formation and staining were conducted according to the microtiter dish biofilm formation
35 assay protocol [38] with minimal modifications relative to growing medium and solvent used for
36 crystal violet dissolution. The experimental set-up differs in the inhibition and eradication assays,
37 the assays will therefore be described separately.
38
39
40
41
42
43
44
45
46

47 **Biofilm inhibition assay**

48
49 96 wells microtiter plates were prepared the day of stimulation, by addition of 10 x peptide (10
50 µl/well), diluted from the stock solution into sterile milliQ water. The overnight bacterial culture
51 was diluted 1:100 and 90 µl/well of this bacterial suspension were added to every well, except for
52
53
54
55
56
57
58
59
60

1
2
3 those used as MHB sterility control. As negative control, 90 μ l/well of cell suspension were added
4
5 to 10 μ l of milliQ water.
6
7
8
9

10 **Biofilm eradication assay**

11
12
13 Overnight bacterial cultures were diluted 1:100 in fresh MHB and 100 μ l/well of this bacterial
14
15 suspension were added to every well, except for those used as MHB sterility control. After
16
17 overnight incubation at 37°C, wells were washed 2 times with PBS, then the peptides diluted in
18
19 MHB were added according to the intended testing dilutions. Plates were then incubated overnight
20
21 at 37°C.
22
23
24
25
26

27 **Biofilm staining with crystal violet**

28
29
30 Once the challenge time elapsed, the wells were washed 2 times with PBS (150 μ l/well) prior to
31
32 staining the attached biofilm with crystal violet (125 μ l/well) for 10 minutes on the bench. The
33
34 unattached staining was removed by aspiration and washing with PBS. Eventually the stain was
35
36 dissolved in ethanol 96% (200 μ l/well) for 10 minutes before transferring 100 μ l/well in a new flat
37
38 bottom plate for reading absorbance at 595 nm.
39
40
41
42
43

44 **Hemolysis assay**

45
46
47 Briefly, donors blood was collected into Vacutainer EDTA coated tubes and centrifuged at 800 g
48
49 for 10 minutes to isolate red blood cells which were washed twice with sterile saline (0.9 % NaCl)
50
51 and then diluted to a concentration of 20% red blood cells in saline.
52

53
54 In sterile conditions, 96 well round bottom polypropylene microtiter plates were filled with 100
55
56 μ l/well of serially two-fold saline-diluted concentrations of peptides. 1 % Triton X100 and 0.9 %
57
58
59

1
2
3 NaCl were used respectively as positive and negative controls of hemolysis. The plate was
4 incubated for 24 hours at 37°C in 5% CO₂ atmosphere to assess ability of peptides to penetrate and
5 disrupt red blood cells membrane, thus releasing the hemoglobin and red coloring the supernatant.
6
7 The day after, the plate was centrifuged at 250 g for 5 minutes and 20 µl of the supernatant were
8 transferred into flat bottomed polystyrene plates, prefilled with 100 µl of saline. Absorbance
9 readings at 546 nm for the different treatments were blank subtracted and reported as percentage of
10 the positive hemolysis control.
11
12
13
14
15
16
17
18
19

20 **LDH assay on HaCaT cell line**

21
22 LDH leakage from treated and untreated cells were determined on supernatants by using the
23 CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega), following manufacturer's
24 instructions. The absorbance is presented as percent of cytotoxicity (absorbance from lysed cells
25 was set as 100%).
26
27
28
29
30
31
32
33
34

35 **CD spectroscopy**

36
37 Circular dichroism (CD) experiments were performed on a J-815 circular dichroism
38 spectropolarimeter (Jasco). Far-UV CD spectra were recorded after five accumulations at 20°C,
39 using a 1-mm path length quartz cell, between 280 and 190 nm at 100 nm/min with a band width of
40 1 nm. All peptides were analyzed in water, in TFE/water (4:1, v/v) and 20 mM SDS.
41
42
43
44
45
46

47 **Statistical analysis**

48
49 Data analysis was performed with Graphpad Prism 6, statistical significance was calculated with t-
50 test by comparison to the untreated control (*: P < 0.05; **: P < 0.01; ***: P < 0.001).
51
52
53
54
55
56

57 **References**

1. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther. Adv. Drug. Saf.* 2014; 5(6): 229–241.
2. WHO European strategic action plan on antibiotic resistance 2011–2016.
3. Barton M.D. Antibiotic use in animal feed and its impact on human health. *Nutr. Res. Rev.* 2000; 13(2): 279–299.
4. Chang Q, Wang W, Regev-Yochay G, Lipsitch M, Hanage W.P. Antibiotics in agriculture and the risk to human health: how worried should we be? *Evol. Appl.* 2015; 8(3): 240–247.
5. Economou V, Gousia P. Agriculture and food animals as a source of antimicrobial-resistant bacteria. *Infect. Drug. Resist.* 2015; 8: 49–61.
6. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. *Nat. Rev. Microbiol.* 2015; 13(1): 42–51.
7. Baltzer SA, Brown MH. Antimicrobial Peptides – Promising Alternatives to Conventional Antibiotics. *J. Mol. Microbiol. Biotechnol.* 2011; 20: 228-235.
8. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. *Clin Microbiol Rev.* 2006 Jul;19(3):491-511.
9. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat. Biotechnol.* 2006; 24: 1551–1557.
10. Guilhelmelli F, Vilela N, Albuquerque P, Derengowski S, Silva-Pereira I, Kyaw CM. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. *Front. Microbiol.* 2013; 4: 353.
11. Wang G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. *J Biol Chem.* 2008 283(47): 32637–32643.
12. Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim. Biophys. Acta* 2006; 1758 (9): 1408–25.

- 1
2
3 13. Xhindoli D, Pacor S, Benincasa M, Scocchi M, Gennaro R, Tossi A. The human cathelicidin
4 LL-37 - A pore-forming antibacterial peptide and host-cell modulator. *Biochim. Biophys.*
5 *Acta* 2016; 1858: 546.
6
7
- 8
9 14. Steinstraesser L, Hirsch T, Schulte M, Kueckelhaus M, Jacobsen F, Mersch EA, Stricker I,
10 Afacan N, Jenssen H, Hancock RE, Kindrachuk J. Innate defense regulator peptide 1018 in
11 wound healing and wound infection. *PLoS One*. 2012;7(8):e39373 Epub 2012 Aug6
12
13
- 14 15. Koczulla R, von Degenfeld G, Kupatt C, Krötz F, Zahler S, Gloe T, Issbrücker K, et al. An
16 angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J. Clin. Invest.* 2003;
17 111(11): 1665–1672.
18
19
- 20 16. Carretero M, Escámez MJ, García M, Duarte B, Holguín A, Retamosa L, Jorcano JL, Del
21 Río M, Larcher F. In vitro and in vivo wound healing-promoting activities of human
22 cathelicidin LL-37 *J. Invest. Dermatol.* 2008; 128(1): 223–236.
23
24
- 25 17. Yang D, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov
26 O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl
27 peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood
28 neutrophils, monocytes, and T cells. *J. Exp. Med.* 2000; 192(7): 1069–1074.
29
30
- 31 18. Afshar M, Gallo RL. Innate immune defense system of the skin. *Vet. Dermatol.* 2013; 24:
32 32–39.
33
34
- 35 19. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? *Br. Jour.*
36 *Dermatol.* 2008; 158(3); 442–455.
37
38
- 39 20. Lai Y, Di Nardo A, Nakatsuji V, Leichtle A, Yang Y, Cogen AL, Wu ZR, *et al.* Commensal
40 bacteria regulate Toll-like receptor 3–dependent inflammation after skin injury. *Nat. med.*
41 2009; 15 (12): 1377-1382.
42
43
- 44 21. Rupp ME. Clinical characteristics of infections in humans due to *Staphylococcus*
45 *epidermidis*, *Methods Mol. Biol.* 2014; 1106: 1–16.
46
47
- 48 22. Grice EA, Segre JA. The skin microbiome. *Nat. Rev. Microbiol.* 2011; 9(4): 244–253.
49
50
51
52
53
54
55
56
57
58
59

- 1
2
3 23. Otto M. Staphylococcus epidermidis—the 'accidental' pathogen. *Nat. Rev. Microbiol.* 2009;
4 7(8): 555-567.
5
6
7 24. Nelson A, Hultenby K, Hell E, Riedel HM, Brismar H, Flock JI, *et al.* Staphylococcus
8 epidermidis isolated from newborn infants express pilus-like structures and are inhibited by
9 the cathelicidin-derived antimicrobial peptide LL37. *Pediatr. Res.* 2009; 66:174–178.
10
11
12 25. Jacobsen AS, Jenssen H. Human cathelicidin LL-37 prevents bacterial biofilm formation,
13 *Future Med. Chem.* 2012; 4(12): 1587–1599.
14
15
16
17 26. Jenssen H, Fjell CD, Cherkasov A, Hancock RE. QSAR modeling and computer-aided
18 design of antimicrobial peptides. *J Pept Sci.* 2008; 14(1):110-4
19
20
21
22 27. Wu WKK, Wang G, Coffelt SB, Betancourt AM, Lee CW, Fan D, Wu K, Yu J, Sung JJY,
23 Cho CH. Emerging Roles of the Host Defense Peptide LL-37 in Human Cancer and its
24 Potential Therapeutic Applications. *Int. J. Cancer.* 2010; 127(8): 1741–1747.
25
26
27 28. Hell E, Giske CG, Nelson A, Römling U, Marchini G. Human cathelicidin peptide LL37
28 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis.
29 *Lett. Appl. Microbiol.* 2010; 50(2): 211–215.
30
31
32 29. Peplow PV, Chatterjee MP. A review of the influence of growth factors and cytokines in
33 vitro human keratinocyte migration. *Cytokine.* 2013; 62: 1–21.
34
35
36 30. Haase I, Evans R, Pofahl R, Watt FM. Regulation of keratinocyte shape, migration and
37 wound epithelialization by IGF-1- and EGF-dependent signalling pathways. *J. Cell.*
38 *Sci.* 2003; 116(15): 3227–3238.
39
40
41 31. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y *et al.*
42 Induction of Keratinocyte Migration via Transactivation of the Epidermal Growth Factor
43 Receptor by the Antimicrobial Peptide LL-37. *J. Immunol.* 2005; 175 (7): 4662-4668.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 32. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A.
4 Protein Identification and Analysis Tools on the ExPASy Server. (In) John M. Walker (ed):
5 The Proteomics Protocols Handbook, Humana Press (2005). pp. 571-607.
6
7
8
9 33. Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research
10 and education. *Nucleic Acids Res.* 2016; 44: 1087-1093.
11
12
13 34. Osorio D, Rondon-Villarreal V, Torres P. Peptides: A package for data mining of
14 antimicrobial peptides. *R. J.* 2015 7(1): 4–14.
15
16
17 35. Cherry MA, Higgins SK, Melroy H, Lee HS, Pokorny A. Peptides with the same
18 composition, hydrophobicity, and hydrophobic moment bind to phospholipid bilayers with
19 different affinities. *J. Phys. Chem. B.* 2014; 118(43): 12462-12470.
20
21
22 36. Vang M, Jenssen H. Optimized scratch assay for test of migration in vitro with optical
23 camera- article submitted.
24
25
26
27
28 37. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the
29 minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat. Protoc.* 2008; 3(2):
30 163–175.
31
32
33
34 38. O’Toole GA. Microtiter Dish Biofilm Formation Assay. *JoVE.* 2011; (47): 2437.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Tables**
4
5

6 **Table 1.** List of peptides used in the study with indication of name, residues position, sequence and
7 MIC values in *S. epidermidis*
8

9 **Table 1.**

Peptide	Residue	Sequence ^a	MIC [$\mu\text{g/ml}$] ^b
LL-37	1-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLPRTES	50
LL-12	1-12	LLGDFFRKSKEK	>100
SK-12	9-20	SKEKIGKEFKRI	>100
FK-12	17-28	<u>FK</u> RIVQRIKDFL	50
KR-12	18-29	<u>KR</u> IVQRIKDFLR	50
VQ-12 ^{V26}	21-32	VQRIK <u>V</u> FLRNLV	50
VQ-12	21-32	VQRIK <u>D</u> FLRNLV	>100
IK-12	24-35	IKDFLRNLPRT	>100
DF-12	26-37	DFLRNLPRTES	>100

32 ^a the C-terminus of all peptides is amidated

33 ^b average from three independent biological replicates
34
35
36
37
38
39
40
41
42

43 **Table 2.** MBC, MIC and MBC/MIC for LL-37, its derivative fragments FK-12, KR-12 and VQ-
44 12^{V26}
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2.

antimicrobial	MBC [$\mu\text{g/ml}$] ^a	MIC [$\mu\text{g/ml}$] ^a	MBC/MIC	activity
LL-37	100	50	2	bactericidal
FK-12	50	50	1	bactericidal
KR-12	50	50	1	bactericidal
VQ-12 ^{V26}	50	50	1	bactericidal

MBC, minimum bactericidal concentration

MIC, minimum inhibitory concentration

^a average from three independent biological replicates

Table 3. Comparison by sequence alignment of active and inactive LL-37 fragments tested as *S. epidermidis* biofilm inhibitors and eradicators

Table 3.

Effective against <i>S. epidermidis</i> biofilm		Not effective against <i>S. epidermidis</i> biofilm	
peptide	sequence	peptide	sequence
		LL-12	LLGDFFRKSKEK
FK-12	FKRIVQRIKDFL	SK-12	SKEKIGKEFKRI
KR-12	KRIVQRIKDFLR	IK-12	IKDFLRNLVPRT
VQ-12 ^{V26}	VQRIK <u>V</u> FLRNLV	VQ-12	VQRIK <u>D</u> FLRNLV
		DF-12	DFLRNLVPRTES

Table 4. Comparison of antimicrobial and hemolytic activity for the peptides used in this study

peptide	MIC [$\mu\text{g/ml}$] ^a	HE ₁₀ [$\mu\text{g/ml}$] ^a	S
FK-12	50	>100	>2
KR-12	50	>100	>2
VQ-12 ^{26v}	50	>100	>2
LL-37	50	50	1

HE₁₀: concentration of antimicrobials causing 10% hemolysis

S: selectivity ratio calculated as ratio of HE₁₀ and MIC concentrations

^a average of three independent biological replicates

Table 5. Physicochemical properties of the LL-37 and LL-37 fragments used in the study.

peptide	Mw [Da] ^a	pI ^a	q ^a	AI ^a	mH ^b	GRAVY ^a	f % ^a	WW H ^c [kcal/mol]	BI ^c [Kcal/mol]	II ^a
LL-37	4493.3	10.61	+6	89.46	0.44	-0.724	35		2.99	23.34
LL-12	1467.7	9.70	+2	65.0	0.38	-0.933	33	3.79	2.81	2.88
LK-12	1462.7	10	+3	65	0.49	-1.375	25	7.2	3.36	9.66
FK-12	1561.9	11.53	+3	121.67	0.68	- 0.1	50	2.04	2.53	3.37
KR-12	1570.9	12.21	+4	121.67	0.75	-0.708	41	ND	4.02	3.37
VQ-12^{V26}	1484.8	12.01	+3	170.00	0.47	-0.633	50	1.26	1.47	21.35
VQ-12	1500.8	11.23	+2	145.83	0.43	-0.008	58	2.42	2.53	22.14
IK-12	1465.7	10.84	+2	121.67	0.40	-0.258	41	2.36	2.62	31.91
DL-12	1445.7	6.73	0	89.17	0.60	-0.667	58	3.83	3.42	71.08

Mw: molecular weight; *pI*: isoelectric point; *q*: net charge; *AI*: aliphatic index; *mH*: mean relative hydrophobic moment; *f%*: total hydrophobic ratio; *GRAVY*: Grand average of hydropathicity; *WW H*: Wimley-White whole-residue hydrophobicity; *BI*: Boman Index; *II*: instability index

^a calculated with EXpasy Protparam.

^b calculated with HydroMCalc using Eisenberg scale

^c calculated with the ADP database Calculation and prediction tab




Figure 1. *S. epidermidis* Biofilm inhibition by LL-37 fragments, a preliminary screening. Diluted overnight cultures of *S. epidermidis* were challenged with the indicated concentrations of test peptides for 20 hours at 37° C in static conditions. The biofilms were stained with crystal violet and the biofilm mass was quantified by OD595 readings. Data represent the mean \pm SEM of 2 biological replicate experiments, each consisting of 4 replicates. (*: P < 0,05; **: P < 0,01)

132x82mm (300 x 300 DPI)






Fig 2. *S. epidermidis* biofilm inhibition. The biofilm inhibitory potential of the best acting LL-37 fragments was compared to the LL-37 peptide itself. Diluted overnight cultures of *S. epidermidis* were challenged with the indicated concentrations of test peptides for 20 hours at 37° C in static conditions. Data were plotted as stained biomass (A) and as percent of biofilm inhibition (B) versus peptides concentrations. Data represent the mean \pm SEM of 2 biological replicate experiments, each consisting of 4 replicates. Statistical significance was calculated with t-test by comparison to the untreated control. (*: $P < 0.05$; **: $P < 0.01$; ***: $P < 0.001$). Data were plotted also as percentage of biofilm inhibition by normalizing the test compounds OD595 readouts to those of the negative control (untreated bacteria cells).

209x237mm (300 x 300 DPI)



43 Figure 3. *S. epidermidis* biofilm eradication. The biofilm eradication potential of the best acting LL-37
 44 fragments was compared to the LL-37 peptide itself. Data were plotted as stained biofilm biomass (A) and
 45 as percent of biofilm eradication (B) versus antimicrobials concentrations. Overnight cultures of *S.*
 46 *epidermidis* in MHB were diluted 1:100 in fresh MHB and plated in 96 well polypropylene plates (100 $\mu\text{l/well}$)
 47 and biofilm was allowed to form during overnight incubation at 37° C in static conditions. Fragments and LL-
 48 37 peptide were added to the *S. epidermidis* biofilm after removal of residual planktonic bacteria and
 49 allowed to react overnight. Data represented here are from 3 biological replicates, each consisting of 4
 replicate wells (*: $P < 0.05$; **: $P < 0.01$; ***: $P < 0.001$).

209x235mm (300 x 300 DPI)



42 Figure 4. LDH release from HaCaT cells. HaCaT-1 cells (2×10^4 cells/well) were incubated in 96 wells micro-
 43 titer plates with antimicrobials at the tested concentrations overnight. The amount of LDH released was
 44 measured by OD490 readouts (A). Data were represented as percentage of toxicity (B) after baseline
 45 subtraction of untreated cells (negative control) and normalization to the lysed cells (positive control),
 46 whose absorbance was set as 100%. Data represented here are from 3 biological replicates, each consisting
 47 of 3 replicate wells. (*: $P < 0.05$; **: $P < 0.01$; ***: $P < 0.001$). The comparison to the untreated cells was
 48 not significant for all the fragments at the tested concentrations.

49 211x231mm (300 x 300 DPI)




Figure 5. RBC hemolysis. The hemoglobin release from red blood cells upon overnight treatment with the test compounds was measured as OD546 readouts (A). Data are reported also as percent of hemolysis after normalization to the lysed cells (B). Data represented here represent mean \pm SEM of triplicate experiments conducted on erythrocytes collected from different donors (*: $P < 0.05$; **: $P < 0.01$; ***: $P < 0.001$).

209x237mm (300 x 300 DPI)





Figure 6. Migration of HaCaT cells as a result of LL-37 fragment treatment. The migration effect of LL-37 fragments were tested at 25 μ g/ml concentration on HaCaT cells in low FBS in a scratch assay. The closure of the gap was measured every hour on an oCelloScope for 24 hours. Pictures of t=0 (top row) and t=24 (bottom row) taken by the oCelloScope (A) Data represent the average of three independent triplicates. Graphic representation of scratch assay (B) (*: P < 0.05; **: P < 0.01; ***: P < 0.001).

47x52mm (300 x 300 DPI)




Figure 7. CD spectra analysis of the test peptides in water and TFE-water (4:1, v/v) Circular dichroism (CD) experiments were performed on a J-815 circular dichroism spectropolarimeter (Jasco). Far-UV CD spectra were recorded after five accumulations at 20°C, using a 1-mm path length quartz cell, between 280 and 190 nm at 100 nm/min with a band width of 1 nm. All peptides were analyzed in water, in TFE/water (4:1, v/v) and 20 mM SDS.

128x155mm (300 x 300 DPI)